Enhanced Antitumor Efficacy Of A Novel Oncolytic Vaccinia Virus Encoding A Fully Monoclonal Antibody Against T-Cell Immunoglobulin And Itim Domain (Tigit)

Background: Oncolytic virotherapy with vaccinia virus (VV) can lead to effective anti-tumor immunity by turning "cold" tumors into "hot" tumors. However, its therapeutic potential is affected by the tumor's local immunosuppressive tumor microenvironment (TME). Therefore, it is necessary to explore the use of immune checkpoint inhibitors to arm oncolytic VVs to enhance their anti-tumor efficacy.Methods: A novel recombinant oncolytic VV, VV-alpha-TIGIT, which encoded a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT) was generated by homologous recombination with a shuttle plasmid. The anti-tumor efficacy of the VV-alpha-TIGIT was investigated in several subcutaneous and ascites tumor models.Findings: The functional alpha-TIGIT was sufficiently produced and secreted by tumor cells infected with VV-alpha-TIGIT, which effectively replicated in tumor cells leading to significant oncolysis. Intratumoral injection of VV-alpha-TIGIT improved anti-tumor efficacy in several murine subcutaneous tumor models compared to VV Control (without alpha-TIGIT insertion). Intraperitoneal injection of VV-alpha-TIGIT achieved approximately 70% of complete tumor regression in an ascites tumor model. At the same time, treatment with VV-alpha-TIGIT significantly increased the recruitment and activation of T cells in TME. Moreover, the in vivo anti-tumor activity of VV-alpha-TIGIT was largely dependent on CD8(+) T cell-mediated immunity. Finally, the tumor-bearing mice cured of VV-alpha-TIGIT treatment resisted rechallenge with the same tumor cells, suggesting a long-term persistence of tumor-specific immunological memory.Interpretation: The recombinant oncolytic virus VV-alpha-TIGIT successfully combines the advantages of oncolytic virotherapy and intratumorally expression of immune checkpoint inhibitor against TIGIT. This novel strategy can provide information on the optimal design of novel antibody-armed oncolytic viruses for cancer immunotherapy. (C) 2021 The Authors. Published by Elsevier B.V.